Mirion Technologies reported its fiscal 2025 Q1 earnings on April 29th, 2025. The company exceeded market revenue expectations with a sales increase of 4.9% year over year, totaling $202 million. Management reiterated its full-year guidance for organic revenue growth, adjusted EBITDA, and adjusted EPS, projecting total revenue growth of 5.0% – 7.0%. Adjusted EPS guidance remains at $0.45 – $0.50 per share, in line with previous forecasts. This performance reflects strong demand from the nuclear power sector and effective operational strategies.
RevenueThe total revenue for
in fiscal Q1 2025 was $202 million, marking a 4.9% increase from the $192.60 million reported in Q1 2024. This growth was driven by both product and service segments, reflecting robust demand and operational efficiency improvements.
Earnings/Net IncomeMirion Technologies returned to profitability with an EPS of $0.00 in Q1 2025, reversing from a loss of $0.13 per share in Q1 2024, a positive change of 101.0%. The net income also saw a significant improvement, swinging from a net loss of $26.5 million in Q1 2024 to a net income of $400,000 in Q1 2025, a 101.5% positive change. The EPS reflects a positive turnaround, indicating stability in earnings.
Post-Earnings Price Action ReviewFollowing Mirion Technologies' Q1 2025 earnings report, the stock displayed positive price movement, with a 1.56% increase during the latest trading day and a 13.19% jump over the past full trading week. Month-to-date, the stock has climbed 4.55%. Historically, a backtest of earnings metrics showed that the 3-day win rate is highest at 55.52% for EPS, while the 10-day win rate peaks at 51.80% for revenue growth. The 30-day win rate for net income is 50.68%, with a maximum return of 7.85% occurring on day 79 post-report. These insights suggest that EPS impacts the stock most immediately, whereas revenue growth influences slightly longer-term gains, and net income offers reliable moderate-term returns.
CEO Commentary"We delivered a strong start to the year, with year-over-year revenue growth and adjusted free cash flow generation," commented Thomas Logan, Chairman and Chief Executive Officer of Mirion Technologies. He noted that order entry accelerated due to robust demand from the nuclear power sector and expressed optimism about the year ahead despite challenges from new tariffs and U.S. government funding reductions. Both operating segments experienced revenue growth, contributing to adjusted EBITDA margin expansion through operational efficiency and procurement savings. Logan highlighted a significant 11.5% year-over-year increase in total orders, excluding potential large orders currently in the bidding process.
GuidanceMirion reaffirms its 2025 guidance, expecting organic revenue growth of approximately 5.5% – 7.5% and total revenue growth of about 5.0% – 7.0%, incorporating a foreign exchange rate headwind. Adjusted EBITDA is anticipated to be between $215 million and $230 million, with an adjusted EBITDA margin of 24.0% – 25.5%. The company projects adjusted free cash flow of approximately $85 million – $110 million and adjusted EPS of around $0.45 – $0.50 per share.
Additional NewsIn recent developments, Mirion Technologies announced the acquisition of Oncospace, an AI-focused radiation oncology software provider, through its Sun Nuclear division. This strategic move aims to enhance Mirion's offerings in the medical segment, particularly in radiation therapy quality assurance. Additionally, the company has been awarded contracts for the TerraPower Natrium® Reactor Demonstration Project, further strengthening its position in the nuclear energy sector. Mirion also achieved ISO 19443 certification at its Munich site, reflecting its commitment to maintaining high standards in operational processes and safety. These initiatives highlight Mirion's focus on expanding its technological capabilities and market reach.
Comments
No comments yet